Cancer pain: An update of pharmacological approaches in pain therapy

Current Opinion in Anaesthesiology

Volumn 15, Issue 5, 2002, Pages 555-561

  Gralow, Ingrid ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cancer pain; Opioid rotation; Pharmacotherapy

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CANNABINOID; CARBAMAZEPINE; CLOMIPRAMINE; CODEINE; DESIPRAMINE; DEXAMETHASONE; FENTANYL; FENTANYL CITRATE; GABAPENTIN; GLUCOCORTICOID; HYDROMORPHONE; IMIPRAMINE; KETAMINE; MAPROTILINE; METHADONE; METHYLPREDNISOLONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE DERIVATIVE; OXYCODONE; PREDNISONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ATAXIA; BONE METASTASIS; BONE PAIN; CANCER PAIN; CONSTIPATION; DRUG INDICATION; DRUG INDUCED DISEASE; GLUCOSE INTOLERANCE; HUMAN; IMMUNE DEFICIENCY; MYOPATHY; NAUSEA; NEUROPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO; VOMITING;

EID: 0036792401     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200210000-00014     Document Type: Review

References (48)

1. Bonica JJ. Cancer pain. In: Bonica JJ, editor. The management of pain. 2nd ed., vol. 1. Philadelphia: Lea und Febiger; 1990. pp. 400-460.
2. Goudas L, Carr DB, Bloch R, Balk E. Management of cancer pain. Evidence report/technology assessment no. 35. AHRQ publication no. 02-E002. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
3. World Health Organization. Cancer pain relief. 2nd ed. Geneva: WHO Office of publication; 1996.
4. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs 2001; 61; 955-977.
5. Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Expert Working Group of the Research Network of the European Association for Palliative Care. Br J Cancer 2001; 84; 5:587-593.
6. Lickiss JN. Approaching cancer pain relief. Eur J Pain 2001; 5 (Suppl A):5-14.
7. Carr DB. The development of national guidelines for pain control: synopsis and commentary. Eur J Pain 2001; 5 (Suppl A):91-98.
8. Breivik H. Opioids in cancer and chronic non-cancer pain therapy: indications and controversies, Acta Anesthesiol Scand 2001; 45:1059-1066.
9. Bruera E, Lawlor P. Cancer pain management. Acta Anaesthesiol Scand 1997; 41:146-153.
10. Fordyce W. Pain in cancer and chronic non-cancer conditions: similarities and differences. Acta Anesthesiol Scand 2001; 45:1086-1089.
11. Caraceni A. Evaluation and assessment of cancer pain and cancer pain treatment. Acta Anesthesiol Scand 2001; 45:1067-1075.
12. MacDonald N, Ayoub J, Farley J, et al. A Quebec survey of issues in cancer pain management. J Pain Symptom Manage 2002; 23:39-47.
13. Woolf CJ, Max MB. Mechanism-based pain diagnosis. Anesthesiology 2001; 95:241-249.
14. Jensen MP, Turner JA, Romano JM, Fisher LD. Comparative reliability and validity of chronic pain intensity measures. Pain 1999; 83:157-162.
15. Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treatment Rev 2001; 27:51-61.
16. McDonnell FJ, Sloan JW, Hamann SR. Advances in cancer pain management. Curr Pain Headache Rep 2001; 5:265-271.
17. Donnelly S, Davis MP, Walsh D, Naughton M. Morphine in cancer pain management: a practical guide. Support Care Cancer 2002; 10:13-35.
18. Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage 2001; 21:397-406.
19. Caraceni A, Portenoy RK, a working group of the IASP Task Force on Cancer Pain. An international survey of cancer pain characteristics and syndromes. Pain 1999; 82:236-274.
20. Bruera E, Schoeller T, Wenk R, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 1995; 10:348-355.
21. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse side effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19:2542-2554.
22. Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001; 93:247-257.
23. Mather LE. Trends in the pharmacology of opioids: implications for the pharmacotherapy of pain. Eur J Pain 2001; 5 (Suppl A):49-57.
24. Wilder-Smith CH. Opioids in cancer pain: which one is best? Support Care Cancer 2001; 9:71-72.
25. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002; 5:127-138.
26. Santiago-Palma J, Khojainova N, Kornick C, et al. Intravenous methadone in the management of chronic cancer pain. Cancer 2001; 92:1919-1925.
27. Streltzer J. Pain management in the opioid-dependent patient. Curr Psychiatr Rep 2001; 3:489-496.
28. Doverty M, Somogyi AA, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 2001; 93:155-163.
29. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002; (1):CD003447.
30. Levy MH. Advancement of opioid analgesia with controlled-release oxycodone. Eur J Pain 2001; 5 (Suppl A): 113-116
31. Payne R, Coluzzi P, Hart L, et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001; 22:575-583.
32. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomised trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 2001; 91:123-130.
33. Lichtor JL, Sevarino FB, Joshi GP, et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 1999; 89:732-738.
34. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83:389-400.
35. Mays TA. Antidepressants in the management of cancer pain. Curr Pain Headache Rep 2001; 5:227-236.
36. Guay DRP. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001; 21:1070-1081.
37. Cohen SP, Abdi S. New developments in the use of tricyclic antidepressants for the management of pain. Curr Opin Anaesthesiol 2001; 14:505-511.
38. Devulder J, Lambert J, Naeyaert JM. Gabapentin for pain control in cancer patients' wound dressing care. J Pain Symptom Manage 2001; 22:622-626.
39. Collins WP, McQuay H, Carroll D, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2000; (3):CD0011133.
40. Gu Y, Huang LM. Gabapentin actions on N-methyl-D-aspartate receptor channels are protein kinase C-dependent. Pain 2001; 93:85-92.
41. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2000; (3):CD001133.
42. Jackson K, Ashby M, Martin P, et al. 'Burst' ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage 2001; 22:834-842.
43. Smith H, Elliot J. Alpha2 receptors and agonists in pain management. Curr Opin Anaesthesiol 2001; 14:513-518.
44. Pavlakis N, Stockler M. Bisphosphonates in breast cancer. Cochrane Database Syst Rev 2002; (1):CD003474.
45. Wooldridge JE, Anderson CM, Perry MC, et al. Corticosteroids in advanced cancer. Oncology 2001; 15:225-236.
46. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2000; (2):CD001219.
47. Campbell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323:13-23.
48. Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323:16-21.